Elizabeth Zinni
Family · Canfield, OHNPI 1225428626
Payments from drug & device makers
Across 579 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- AstraZeneca$839
- Lilly USA, LLC$774
- Amgen$752
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$536
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,725100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 66 | $1,195 |
| Novo Nordisk | 73 | $1,144 |
| AstraZeneca | 47 | $839 |
| Lilly USA, LLC | 54 | $774 |
| Amgen(2 entities) | 48 | $752 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $536 |
| Corcept Therapeutics | 21 | $495 |
| Abbott | 22 | $351 |
| Azurity Pharmaceuticals, Inc. | 24 | $317 |
| Exact Sciences | 13 | $303 |
| GSK | 23 | $283 |
| Boehringer Ingelheim | 16 | $273 |
| Johnson & Johnson | 16 | $251 |
| Pfizer | 12 | $204 |
| Sumitomo Pharma America, Inc. | 13 | $202 |
| Novartis | 12 | $183 |
| Otsuka America Pharmaceutical, Inc. | 8 | $175 |
| Xeris Pharmaceuticals, Inc. | 7 | $139 |
| Arbor Pharmaceuticals, Inc. | 5 | $134 |
| Sanofi-aventis U.S. LLC | 8 | $132 |
| Esperion Therapeutics, Inc. | 7 | $113 |
| E.r. Squibb & Sons, L.L.C. | 7 | $112 |
| Bayer | 5 | $111 |
| Recordati_rare_diseases_inc. | 4 | $101 |
| Almatica Pharma LLC | 5 | $79 |
| Sunovion Pharmaceuticals Inc. | 6 | $78 |
| Shield Therapeutics Inc | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Mylan Specialty L.p. | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $40 |
| Merck | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
How this compares
$9,725 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $132,696 |
| OzempicSemaglutide | 86 | $98,440 |
| XareltoRivaroxaban | 39 | $46,482 |
| MounjaroTirzepatide | 39 | $39,220 |
| JardianceEmpagliflozin | 37 | $38,399 |
| JanuviaSitagliptin Phosphate | 32 | $34,139 |
| Repatha SureclickEvolocumab | 33 | $31,226 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $24,743 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $23,393 |
| FarxigaDapagliflozin Propanediol | 12 | $19,105 |
| VraylarCariprazine Hcl | 11 | $15,641 |
| EdarbiAzilsartan Medoxomil | 25 | $13,931 |
| Valsartan | 261 | $7,097 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $6,682 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $6,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $204 | $132,696132 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $1,144 | $102,32499 claims |
| Johnson & JohnsonXarelto | $251 | $46,48239 claims |
| Lilly USA, LLCMounjaro | $774 | $39,22039 claims |
| Boehringer IngelheimJardiance | $273 | $38,39937 claims |
| MerckJanuvia | $28 | $34,13932 claims |
| GSKTrelegy Ellipta | $283 | $23,39319 claims |
| AstraZenecaFarxiga | $839 | $19,10512 claims |
| AbbVieVraylar, Synthroid | $1,195 | $17,99553 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $134 | $13,93125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Canfield
- Melissa WillsCanfield$15K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.